HopeStage
Back to all studies
Active Not RecruitingNCT06308653

Psilocybin for Major Depressive Disorder (MDD)

Researchers are comparing Psilocybin 25 mg, Psilocybin 5 mg and placebo to find out how the approaches affect depression symptoms in adults with depression.

Medication studyAges 18+United States
The study in practice

Understand this study

What is this study about?

Researchers are comparing Psilocybin 25 mg, Psilocybin 5 mg and placebo to find out how the approaches affect depression symptoms in adults with depression.

Who could participate?

Listed age limits: from 18 years.

Listed locations
Birmingham and 28 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: March 13, 2024
Recruitment status
Active Not Recruiting
Enrollment listed in the registry
238
Sponsor
Usona Institute
Sponsor type
Research institute
Study type
Drug
Intervention type
Behavioural, Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT06308653
Official title
Show the full official title

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)

Recruitment & locations

Not recruiting

Birmingham · Fayetteville · Little Rock

25 more locations
  • La Jolla
  • Los Angeles
  • Santa Monica
  • Denver
  • New Haven
  • Jacksonville
  • Lauderhill
  • Orlando
  • Atlanta
  • Decatur
  • Chicago
  • Baltimore
  • Rockville
  • St Louis
  • Omaha
  • Princeton
  • Albuquerque
  • New York
  • The Bronx
  • Plano
  • San Antonio
  • Draper
  • Murray
  • Bellevue
  • Vancouver

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

Researchers are comparing Psilocybin 25 mg, Psilocybin 5 mg and placebo to find out how the approaches affect depression symptoms in adults with depression.

Who is behind this study?

The study sponsor is Usona Institute, a research institute.

Does this study involve medication?

Yes. The study involves medication, including Psilocybin 25 mg, Inactive Placebo and Psilocybin 5 mg.

Who can participate?

Listed age limits: from 18 years.

Is this study still recruiting?

The registry lists this study as active, but no longer recruiting.

Want to explore more studies?

Explore studies